Kelly Clarkson's Ex-Husband Brandon Blackstock Dead At 48 What You're Really Eating When You Order Taco Bell Helicopter ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

A slew or company results were causing big market moves ahead of the opening bell Thursday, and for many, earnings-beat ...

U.S. equities slipped midday Thursday as corporate earnings and fresh tariff announcements from President Donald Trump drove ...

The tariffs are Trump’s way of getting drug companies to move more of their operations to the U.S. at a time when domestic ...

Lilly has been chasing—and gaining on—its chief metabolic medicine rival Novo Nordisk and its counterpart GLP-1s Ozempic and ...

The Dow and S&P 500 faced a slight dip. However, Nasdaq managed a record high close. Eli Lilly shares fell due to ...

Sales grew 38% year over year, driven by volume growth from weight-loss and diabetes drugs Zepbound and Mounjaro, Lilly said.

Earnings season marches on, with Eli Lilly among the big names yet to report this week. President Trump has said he will name replacements this week for Federal Reserve governor Adriana Kugler and [Bu ...